EBV LMP-1 Activators
Epstein-Barr virus (EBV) latent membrane protein 1 (LMP-1) is a multifunctional integral membrane protein encoded by the EBV genome. It is primarily expressed in EBV-associated malignancies and plays a crucial role in the pathogenesis of EBV-related diseases, including Hodgkin's lymphoma, Burkitt's lymphoma, and nasopharyngeal carcinoma. LMP-1 functions as a constitutively active mimic of the tumor necrosis factor receptor (TNFR) superfamily, possessing structural and functional similarities to TNFRs. Through its cytoplasmic C-terminal domain, LMP-1 engages various signaling pathways, including NF-κB, MAPK, and PI3K/Akt, leading to the dysregulation of cellular processes such as proliferation, survival, and immune evasion. Additionally, LMP-1 acts as a potent activator of host cell signaling networks, contributing to the oncogenic transformation of infected cells and the establishment of persistent EBV infection.
Activation of EBV LMP-1 occurs through its oligomerization and recruitment of downstream signaling molecules upon ligand-independent receptor clustering. Upon membrane localization, LMP-1 undergoes homo-oligomerization, leading to the formation of signaling complexes that recruit TNFR-associated factors (TRAFs) and other adapter proteins. This clustering event initiates a cascade of intracellular signaling events, including the activation of NF-κB, MAPK, and PI3K/Akt pathways, which culminate in the transcriptional upregulation of target genes involved in cell proliferation, survival, and immune evasion. Furthermore, LMP-1-mediated activation of cellular signaling pathways promotes the expression of anti-apoptotic proteins and immunomodulatory factors, contributing to the evasion of host immune surveillance and facilitating viral persistence. Overall, the activation of EBV LMP-1 represents a critical event in EBV-associated oncogenesis, highlighting its pivotal role in the dysregulation of cellular signaling pathways and the establishment of viral-associated malignancies.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sotrastaurin | 425637-18-9 | sc-474229 sc-474229A | 5 mg 10 mg | $300.00 $540.00 | ||
Sotrastaurin is a protein kinase C inhibitor with immunosuppressive properties. By modulating PKC, it may indirectly enhance NF-κB activity, which is downstream of PKC signaling in T-cells. Increased NF-κB activity can lead to upregulation of pro-survival and proliferative signals. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin is a protein synthesis inhibitor known to activate stress-activated protein kinases such as JNK. By stressing cells, it may incidentally upregulate JNK signaling, leading to activation of transcription factors and subsequent gene expression that might parallel some LMP-1 activities. | ||||||
Bryostatin 1 | 83314-01-6 | sc-201407 | 10 µg | $245.00 | 9 | |
Bryostatin 1 is a kinase C activator which potentially enhances the activation of NF-κB. Its activation of PKC could mimic some of the signaling pathways activated by LMP-1, including survival and proliferation. | ||||||
Ingenol 3-angelate | 75567-37-2 | sc-364214 sc-364214A | 1 mg 5 mg | $189.00 $734.00 | 3 | |
Ingenol 3-angelate, a PKC activator, is known for its pro-inflammatory effects, which might involve NF-κB pathway activation. As such, it could potentially activate downstream signaling pathways similar to those activated by the CD40 receptor. | ||||||
2-Amino-6-chloro-α-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic Acid Ethyl Ester | 305834-79-1 | sc-479756 | 25 mg | $380.00 | ||
This compound, also called SC79, is a unique Akt activator that prevents the translocation of Akt to the plasma membrane, thus indirectly activating Akt signaling. By promoting Akt activation, SC79 may mimic some downstream effects of LMP-1 activation. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a well-known activator of PKC which in turn can activate NF-κB. Its ability to modulate PKC might parallel the activation profile of CD40 signaling pathways. | ||||||
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $71.00 $202.00 | 18 | |
SB 216763 is a glycogen synthase kinase-3 (GSK-3) inhibitor, which might indirectly activate NF-κB and JNK pathways by inhibiting their negative regulator GSK-3. This could contribute to the activation of pathways typically engaged by LMP-1. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib, while primarily a kinase inhibitor, can affect multiple intracellular pathways and might inadvertently activate some signaling cascades such as p38 MAP kinase due to compensatory cellular mechanisms. | ||||||
UCN-01 | 112953-11-4 | sc-202376 | 500 µg | $251.00 | 10 | |
UCN-01 is a protein kinase inhibitor with complex effects on signal transduction pathways and may indirectly activate JNK and p38 MAP kinase pathways through stress responses or off-target effects. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Resveratrol is known to modulate a variety of intracellular targets, including NF-κB, and might activate signaling pathways involved in cell survival and proliferation, possibly mimicking some effects of CD40 engagemen | ||||||